Molecular Competitors

Stocks . USA . 
Stock . Molecular Partners AG
MOLN Stock  USD 4.21  0.08  1.94%   
Molecular Partners competes with Elicio Therapeutics, Corbus Pharmaceuticals, Milestone Pharmaceuticals, Cardiff Oncology, and Rani Therapeutics; as well as few others. The company conducts business under Biotechnology sector and is part of Health Care industry. Analyzing Molecular Partners competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Molecular Partners to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Molecular Partners Correlation with its peers.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Molecular Partners competition on your existing holdings.
  
Build AI portfolio with Molecular Stock
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
0.214.148.29
Details
Intrinsic
Valuation
LowRealHigh
1.475.629.77
Details

Molecular Partners Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Molecular Partners and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Molecular and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Molecular Partners does not affect the price movement of the other competitor.

High positive correlations

CRBP
+ 0.88
APLT
SAVA
+ 0.88
CRBP
ELTX
+ 0.87
APLT
CRBP
+ 0.83
ELTX
NKTX
+ 0.79
APLT
SAVA
+ 0.79
APLT
  

High negative correlations

SAVA
- 0.68
CRDF
PEPG
- 0.68
APLT
SAVA
- 0.59
PEPG
CRDF
- 0.56
CRBP
PEPG
- 0.55
RANI
PEPG
- 0.55
ELTX

Risk-Adjusted Indicators

There is a big difference between Molecular Stock performing well and Molecular Partners Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Molecular Partners' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
APLT  7.34 (3.26) 0.00 (0.57) 0.00 
 0.00 
 13.33 
(15.73)
 85.17 
ELTX  2.50 (0.44) 0.00 (0.24) 0.00 
 0.00 
 4.65 
(4.34)
 21.98 
CRBP  3.08 (1.31) 0.00 (1.59) 0.00 
 0.00 
 4.60 
(8.37)
 32.00 
MIST  3.33  0.00  0.01  0.11  4.48 
(3.72)
 6.15 
(5.91)
 34.31 
CRDF  3.22  0.25  0.10  0.25  2.98 
(3.89)
 9.28 
(5.34)
 20.56 
RANI  12.42  3.52  0.57  0.64  5.78 
(19.04)
 26.67 
(12.65)
 264.02 
NKTX  2.40 (0.42) 0.00 (0.17) 0.00 
 0.00 
 4.31 
(5.96)
 16.16 
PEPG  4.76  0.14  0.03  0.21  6.06 
(4.64)
 10.14 
(9.44)
 31.03 
SAVA  4.13 (1.33) 0.00 (0.40) 0.00 
 0.00 
 7.27 
(7.56)
 35.02 
ALEC  4.11 (0.85) 0.00 (0.16) 0.00 
 0.00 
 5.63 
(8.33)
 58.73 
All Fundamental Data

Molecular Partners Competitive Analysis

The better you understand Molecular Partners competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Molecular Partners' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Molecular Partners' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
MOLN APLT ELTX CRBP MIST CRDF RANI NKTX PEPG SAVA
 1.94 
 4.21 
Molecular
 0.30 
 0.10 
Applied
 3.35 
 8.03 
Elicio
 4.03 
 8.26 
Corbus
 5.18 
 2.03 
Milestone
 2.09 
 2.81 
Cardiff
 1.41 
 1.40 
Rani
 0.98 
 2.07 
Nkarta
 8.04 
 5.15 
PepGen
 4.88 
 2.15 
Cassava
Market Volatility
(90 Days Market Risk)
Moderately volatile
Out of control
Somewhat reliable
Somewhat reliable
Dangerous
Very risky
Out of control
Very risky
Relatively risky
Very risky
Market Performance
(90 Days Performance)
Soft
Weakest
Weakest
Weakest
Weak
Fair
Fair
Weakest
Soft
Weakest
Odds of Financial Distress
(Probability Of Bankruptcy)
Low
Risky
Risky
Low
Risky
Low
Strong
Strong
Low
Moderate
Current Valuation
(Equity Enterprise Value)
Under Valued
Under Valued
Under Valued
Under Valued
Over Valued
Over Valued
Under Valued
Fairly Valued
Under Valued
Under Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Strong Sell
Strong Sell
Hold
Cautious Hold
Strong Sell
Sell
Hold
Sell
Strong Sell
Strong Sell
Current Ratio
14.37
1.49
N/A
3.86
21.26
15.02
14.02
31.66
11.01
23.41
Net Asset
158.53 M
86.69 M
28.18 M
155.88 M
75.5 M
97.19 M
36.63 M
501.2 M
150.88 M
157.53 M
Profit Margin
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
EBITDA
(51.65 M)
(104.3 M)
(50.27 M)
(37.74 M)
(37.83 M)
(48.25 M)
(50.52 M)
(119.04 M)
(89.09 M)
(141.15 M)
Current Valuation
29.21 M
5.09 M
128.03 M
38.32 M
139 M
133.74 M
158.76 M
(50.85 M)
244.26 M
(18.72 M)
Price To Book
1.31
7.72
35.01
1.52
8.02
3.96
23.87
0.46
2.39
1.26
Operating Margin
N/A
-17.97
N/A
N/A
N/A
-99.78
-34.18
N/A
N/A
N/A
Retained Earnings
(246.29 M)
(574.21 M)
(194.1 M)
(476.89 M)
(367.55 M)
(384.18 M)
(102.91 M)
(544.22 M)
(271.46 M)
(405.11 M)
Current Asset
N/A
37.74 M
N/A
12.71 M
110.42 M
16.9 M
N/A
N/A
N/A
N/A
Beta
0.59
2.09
2.15
2.78
0.44
1.4
0.44
0.61
1.92
-1.09
Number Of Employees
158
28
32
28
33
32
105
105
57
30
Shares Outstanding
37.4 M
144.3 M
17.26 M
17.55 M
85.17 M
67.36 M
97.55 M
71.03 M
68.75 M
48.31 M
Cash Flow From Operations
(59.25 M)
(84.31 M)
(37.07 M)
(41.79 M)
(28.85 M)
(37.69 M)
(35.5 M)
(99.7 M)
(82.37 M)
(116.93 M)
Total Debt
2.44 M
2.79 M
26.04 M
3.24 M
54.8 M
1.52 M
29.71 M
80.27 M
18.66 M
11.83 M
Return On Equity
-0.51
-6.8
-600.13
-0.56
-2.61
-1.03
-11.88
-0.27
-0.62
-0.89
Return On Asset
-0.27
-0.88
-0.79
-0.35
-0.42
-0.53
-0.96
-0.15
-0.34
-0.3
Number Of Shares Shorted
16.7 K
6.63 M
1.06 M
1.31 M
8.25 M
15.65 M
13.89 M
6.02 M
2.76 M
7.22 M
Book Value Per Share
3.19
-0.004
0.22
7.35
0.2
0.73
-0.16
4.76
2.37
3.02
Current Liabilities
N/A
11.19 M
N/A
3.63 M
7.17 M
4.78 M
N/A
N/A
N/A
N/A
Total Asset
158.53 M
86.69 M
28.18 M
155.88 M
75.5 M
97.19 M
36.63 M
501.2 M
150.88 M
157.53 M
Debt To Equity
0.02
0.14
N/A
0.61
0.006
0.024
0.18
0.17
N/A
N/A
Short Ratio
4.02
0.62
10.21
2.8
0.87
14.61
5.43
9.04
4.48
2.72
Target Price
10.73
0.25
15.5
42.33
6.6
10.0
9.25
11.25
10.0
8.0
Shares Owned By Institutions
9.57
66.27
11.93
56.86
50.84
34.28
27.74
85.49
91.75
24.63
Market Capitalization
155.79 M
14.53 M
133.58 M
140.25 M
164.38 M
193.32 M
182.74 M
154.84 M
384.99 M
142.03 M
Price To Earning
1.85
-7.46
N/A
-8.87
-4.44
-0.48
N/A
N/A
N/A
N/A
Price To Earnings To Growth
N/A
N/A
N/A
N/A
N/A
N/A
0.68
N/A
N/A
-0.21
Price To Sales
199.56
14.53
N/A
163.32
77.32
385.88
152.28
1000000.0
N/A
N/A
Net Income
(54.04 M)
(105.62 M)
(51.9 M)
(40.21 M)
(41.52 M)
(45.43 M)
(56.58 M)
(108.79 M)
(89.98 M)
(24.34 M)
Earnings Per Share
-2.02
-0.1
-3.11
-5.49
-0.79
-0.79
-0.77
-1.38
-2.82
-2.22
Shares Owned By Insiders
N/A
5.49
36.77
0.49
3.31
5.97
5.73
0.44
0.17
12.78
Revenue
4.97 M
455 K
N/A
N/A
N/A
683 K
1.03 M
N/A
N/A
N/A
Working Capital
143.5 M
56.35 M
9.17 M
141.16 M
65.8 M
81.63 M
9.85 M
254.42 M
107.06 M
124.78 M
Cash And Equivalents
267.13 M
67.72 M
N/A
66.23 M
86.24 M
122.01 M
98.17 M
412.95 M
218.82 M
197.23 M
Cash Per Share
8.22
1.41
N/A
0.53
2.87
2.82
3.97
8.49
9.26
4.92
Gross Profit
(40.4 M)
(38.06 M)
N/A
(32.96 M)
N/A
(39.47 M)
1.2 M
(36.22 M)
N/A
(56.99 M)
Day Typical Price
4.18
0.0996
7.91
8.17
1.98
2.81
1.4
2.07
5.28
2.14
Accumulation Distribution
77.82
0.011
3562.23
15610.85
352993.0
23888.49
39776.15
15586.51
61971.96
41102.79
Market Facilitation Index
0.0
0.0011
0.0
0.0
N/A
N/A
N/A
N/A
0.0
N/A
Daily Balance Of Power
0.6667
0.2727
0.4333
0.6154
0.5556
(0.50)
(0.40)
0.3333
(0.90)
0.8333
Period Momentum Indicator
0.08
3.0E-4
0.26
0.32
0.1
(0.06)
(0.02)
0.02
(0.45)
0.1
Rate Of Daily Change
1.02
1.0
1.03
1.04
1.05
0.98
0.99
1.01
0.92
1.05
Day Median Price
4.17
0.0995
7.85
8.13
1.96
2.81
1.4
2.07
5.35
2.13
Price Action Indicator
0.08
7.0E-4
0.31
0.29
0.12
(0.03)
(0.01)
0.01
(0.42)
0.07
Coefficient Of Variation
1829.23
(473.67)
(1,207)
(390.64)
2965.06
939.44
782.25
(1,311)
2058.29
(533.47)
Mean Deviation
2.94
7.34
2.5
3.08
3.33
3.22
12.42
2.4
4.76
4.13
Jensen Alpha
0.2648
(3.26)
(0.44)
(1.31)
7.0E-4
0.2482
3.52
(0.42)
0.141
(1.33)
Total Risk Alpha
(0.43)
(4.74)
(0.86)
(1.97)
(0.59)
(0.22)
(0.95)
(0.76)
(0.68)
(1.90)
Sortino Ratio
0.0276
N/A
N/A
N/A
0.0083
0.1009
0.5696
N/A
0.0283
N/A
Downside Variance
15.09
N/A
N/A
N/A
21.56
10.89
53.16
N/A
41.42
N/A
Standard Deviation
4.16
12.88
3.54
4.75
4.71
4.26
33.43
3.22
6.23
5.52
Kurtosis
3.71
13.6
5.62
11.45
4.54
1.17
48.87
0.922
0.3449
3.51
Potential Upside
4.73
13.33
4.65
4.6
6.15
9.28
26.67
4.31
10.14
7.27
Treynor Ratio
(0.50)
(0.57)
(0.24)
(1.59)
0.1106
0.2504
0.6357
(0.17)
0.2125
(0.40)
Maximum Drawdown
26.47
85.17
21.98
32.0
34.31
20.56
264.02
16.16
31.03
35.02
Variance
17.27
165.93
12.53
22.57
22.17
18.11
1117.36
10.38
38.78
30.45
Market Risk Adjusted Performance
(0.49)
(0.56)
(0.23)
(1.58)
0.1206
0.2604
0.6457
(0.16)
0.2225
(0.39)
Risk Adjusted Performance
0.0469
(0.14)
(0.05)
(0.17)
0.0323
0.0835
0.1001
(0.05)
0.0432
(0.12)
Skewness
0.9891
(2.76)
(1.31)
(2.31)
(0.21)
0.9529
6.69
(0.43)
0.2847
(0.76)
Semi Deviation
3.47
N/A
N/A
N/A
4.48
2.98
5.78
N/A
6.06
N/A
Information Ratio
0.0258
(0.22)
(0.12)
(0.28)
0.0082
0.0782
0.1242
(0.11)
0.0293
(0.21)
Value At Risk
(5.45)
(15.73)
(4.34)
(8.37)
(5.91)
(5.34)
(12.65)
(5.96)
(9.44)
(7.56)
Expected Short fall
(3.27)
N/A
N/A
N/A
(3.72)
(3.89)
(19.04)
N/A
(4.64)
N/A
Downside Deviation
3.88
N/A
N/A
N/A
4.64
3.3
7.29
N/A
6.44
N/A
Semi Variance
12.03
N/A
N/A
N/A
20.05
8.88
33.39
N/A
36.67
N/A

Molecular Partners Competition Performance Charts

Five steps to successful analysis of Molecular Partners Competition

Molecular Partners' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Molecular Partners in relation to its competition. Molecular Partners' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Molecular Partners in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Molecular Partners' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Molecular Partners, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Molecular Partners position

In addition to having Molecular Partners in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Air Thematic Idea Now

Air
Air Theme
Companies specializing in air services and air delivery. The Air theme has 21 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Air Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Molecular Partners offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Molecular Partners' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Molecular Partners Ag Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Molecular Partners Ag Stock:
How To Invest In Molecular
Details
Is Molecular Stock a good investment?
Details
What is Molecular Partners' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out Molecular Partners Correlation with its peers.
You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Molecular Partners. If investors know Molecular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Molecular Partners listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Molecular Partners is measured differently than its book value, which is the value of Molecular that is recorded on the company's balance sheet. Investors also form their own opinion of Molecular Partners' value that differs from its market value or its book value, called intrinsic value, which is Molecular Partners' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Molecular Partners' market value can be influenced by many factors that don't directly affect Molecular Partners' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Technical
Analysis
Details
Please note, there is a significant difference between Molecular Partners' value and its price as these two are different measures arrived at by different means. Investors typically determine if Molecular Partners is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Molecular Partners' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY